- Home
- GHI vs ZNTL Comparison
GHI vs ZNTL Comparison
Compare GHI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- ZNTL
- Stock Information
- Founded
- GHI 1998
- ZNTL 2014
- Country
- GHI United States
- ZNTL United States
- Employees
- GHI N/A
- ZNTL N/A
- Industry
- GHI Finance: Consumer Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- ZNTL Health Care
- Exchange
- GHI Nasdaq
- ZNTL Nasdaq
- Market Cap
- GHI 252.3M
- ZNTL 227.0M
- IPO Year
- GHI N/A
- ZNTL 2020
- Fundamental
- Price
- GHI $10.65
- ZNTL $2.92
- Analyst Decision
- GHI Strong Buy
- ZNTL Buy
- Analyst Count
- GHI 4
- ZNTL 8
- Target Price
- GHI $17.50
- ZNTL $10.50
- AVG Volume (30 Days)
- GHI 108.2K
- ZNTL 997.7K
- Earning Date
- GHI 11-06-2024
- ZNTL 11-12-2024
- Dividend Yield
- GHI 13.75%
- ZNTL N/A
- EPS Growth
- GHI N/A
- ZNTL N/A
- EPS
- GHI 0.61
- ZNTL N/A
- Revenue
- GHI $34,307,528.00
- ZNTL $40,560,000.00
- Revenue This Year
- GHI N/A
- ZNTL N/A
- Revenue Next Year
- GHI $10.35
- ZNTL N/A
- P/E Ratio
- GHI $17.42
- ZNTL N/A
- Revenue Growth
- GHI 28.98
- ZNTL N/A
- 52 Week Low
- GHI $10.32
- ZNTL $2.66
- 52 Week High
- GHI $17.48
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- GHI 33.30
- ZNTL 38.90
- Support Level
- GHI $10.32
- ZNTL $3.01
- Resistance Level
- GHI $11.53
- ZNTL $4.00
- Average True Range (ATR)
- GHI 0.37
- ZNTL 0.27
- MACD
- GHI -0.03
- ZNTL -0.07
- Stochastic Oscillator
- GHI 20.12
- ZNTL 8.44
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.